FDA	Food and Drug Administration,
MDSCs	myeloid-derived suppressor cells,
JAK1	Janus kinase 1,
JAK2	Janus kinase 2,
B2M	beta-2-microglobulin,
MHC-I	major histocompatibility complex class 1,
STAT1	signal transducer and activator of transcription 1,
IFNGR1	interferon gamma receptor 1,
PTPN2	protein tyrosine phosphatase non-receptor type 2,
APLNR	apelin receptor,
PBRM1	polybromo 1,
ARID2	AT-rich interaction domain 2,
BRD7	bromodomain containing 7,
USP22	ubiquitin-specific peptidase 22,
PTEN	phosphatase and tensin homolog,
CDKN2A	cyclin-dependent kinase inhibitor 2A,
SK1	sphingosine kinase-1,
HLA-I	human leukocyte antigen class I,
APM	antigen-processing machinery,
NGFR	nerve growth factor receptor,
FMT	fecal microbiome transplantation,
TMB	tumor mutation burden,
ADAR1	adenosine deaminase acting on RNA 1,
ICAM1	intercellular adhesion molecule 1,
AUC	area under curve,
CAFs	cancer-associated fibroblasts,
BLIMP-1	B lymphocyte-induced maturation protein-1,
TIM3	T cell immunoglobulin domain and mucin domain 3,
BTLA	B and T lymphocyte associated,
TAMs	tumor-associated macrophages,
irAEs	immune-related adverse events,
DCs	dendritic cells,
STAT5	signal transducer and activator of transcription 5,
SHIP1	Src homology-2 domain-containing inositol 5-phosphatase 1,
SOCS1	suppressor of cytokine signaling 1,
BACH1	BTB domain and CNC homolog 1,
CEBPB	CCAAT enhancer binding protein beta,
IL7R	interleukin 7 receptor,
NF-κB	nuclear factor kappa B,
AP-1	activator protein 1,
PTPRC	protein tyrosine phosphatase receptor type C,
BCL6	B-cell lymphoma-6 protein,
IL13Rα1	interleukin 13 receptor alpha1,
AKT1	AKT serine/threonine kinase 1,
IRAK1	interleukin 1 receptor-associated kinase 1,
TRAF6	TNF receptor-associated factor 6,
STAT6	signal transducer and activator of transcription 6,
IRF4	interferon regulatory factor 4,
PPAR-γ	peroxisome proliferator activated receptor gamma,
KLF13	Kruppel-like factor 13,
LIPA	lysosomal acid lipase A,
EVs	extracellular vesicles,
SMAD7	SMAD family member 7,
IGF2R	insulin-like growth factor 2 receptor,
VEGFA	vascular endothelial growth factor A,
FGF2	fibroblast growth factor 2,
NLK	Nemo-like kinase,
ULBP2	UL16 binding protein 2,
TAP1	antigen processing 1,
HLA-A	major histocompatibility complex class I, A,
BMDCs	bone marrow-derived dendritic cells,
cDC1s	conventional DC1s,
CXCL	C-X-C motif ligand,
MMPs	matrix metalloproteinases,
JNK	c-Jun N-terminal kinase,
MITF	microphthalmia-associated transcription factor,
TYR	tyrosinase,
MLANA	Melan-A/Mart-1,
CTL	cytolytic T lymphocytes,
TRAF6	TNFR-associated factor 6,
IRAK1/2	Il-1R-associated kinase 1/2.